FOXP3 and systemic lupus erythematosus: Overall, our data is in line with a clinical trial study that showed NAC, when given as adjunct therapy in SLE, decreases inflammation and disease activity and also restores the redox axis in T cells by inducing the expression of FOXP3 and reducing p-mTOR [46].